Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

268
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
268
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

244
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
244
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

3.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

264
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
264
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

214
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
214

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Onychomycosis in Diabetics: A Common Infection with Potentially Serious Complications.

Life (Basel, Switzerland)·2025
Same author

Artificial Intelligence and Large Language Models in the Fight Against Superficial Fungal Infections: Friend or Foe?

Clinical, cosmetic and investigational dermatology·2025
Same author

Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us.

PloS one·2025
Same author

Onychomycosis in special populations.

Future microbiology·2025
Same author

Management and Genetics of Alopecia Areata within the USA: A Cross-Sectional Study of All of Us.

Skin appendage disorders·2025
Same author

A Canadian Algorithm on the Management of Telogen Effluvium.

Journal of cutaneous medicine and surgery·2025

Related Experiment Video

Updated: Jun 18, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

OtezlaTM (Apremilast 30-Mg Tablets).

William Abramovits1,2, Aditya K Gupta3,4, Kimberly Dawn Vincent5

  • 1Department of Medicine, Baylor Scott & White University Hospital, Dallas, TX.

Skinmed
|August 1, 2024
PubMed
Summary

Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for psoriatic arthritis, plaque psoriasis, and Behcet's disease. This review examines its potential for treating other unapproved dermatologic conditions.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

639

Related Experiment Videos

Last Updated: Jun 18, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.0K
Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination
06:02

Author Spotlight: Development and Evaluation of a Cationic Nanoemulsion-Encapsulated Retinoic Acid System for Mucosal Vaccination

Published on: February 23, 2024

639

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Otezla (apremilast) is approved for psoriatic arthritis, plaque psoriasis, and Behcet's disease.
  • Apremilast targets phosphodiesterase-4 (PDE4), an enzyme implicated in inflammatory skin conditions.
  • Existing approvals highlight apremilast's efficacy in specific dermatologic and autoimmune diseases.

Purpose of the Study:

  • To review the potential therapeutic utility of apremilast.
  • To explore its application in dermatologic indications beyond current approvals.
  • To assess the scientific rationale for expanding apremilast's use.

Main Methods:

  • Literature review of existing studies on apremilast.
  • Analysis of phosphodiesterase-4 inhibition mechanism.
  • Evaluation of pathogenesis in various dermatologic conditions.

Main Results:

  • Apremilast's mechanism of action suggests broad anti-inflammatory effects.
  • Evidence supports its potential in other inflammatory dermatoses.
  • Further clinical investigation is warranted for unapproved indications.

Conclusions:

  • Apremilast demonstrates potential for treating additional dermatologic conditions.
  • Its phosphodiesterase-4 inhibitory action is relevant to multiple inflammatory skin diseases.
  • Expanded use of apremilast may benefit patients with unmet needs.